Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

BACKGROUND: Ivacaftor is the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator demonstrating clinical benefit in patients with cystic fibrosis (CF). As ivacaftor is intended for chronic, lifelong use, understanding long-term effects is important for patients and healthcare p...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Thorax
Главные авторы: Bessonova, Leona, Volkova, Nataliya, Higgins, Mark, Bengtsson, Leif, Tian, Simon, Simard, Christopher, Konstan, Michael W, Sawicki, Gregory S, Sewall, Ase, Nyangoma, Stephen, Elbert, Alexander, Marshall, Bruce C, Bilton, Diana
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2018
Предметы:
Cystic Fibrosis
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6204955/
https://ncbi.nlm.nih.gov/pubmed/29748252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2017-210394
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы